Dihydrocapsiate 作为二氢 capsinoid 家族的化合物，是一种口服活性TRPV1激动剂。Dihydrocapsiate 可用于代谢疾病的研究。
| 生物活性 | Dihydrocapsiate, as a compound of capsinoid family, is an orally activeTRPV1agonist. Dihydrocapsiate can be used for the research of metabolism disease[1]. |
| IC50& Target[1] | |
体外研究
(In Vitro) | Dihydrocapsiate (10, 25 and 50 μM; 48 hours; human preadipocytes) does not affect cell viability[1].
Dihydrocapsiate (10 and 20 μM; 8 days; mature adipocytes) markedly decreases the expression levels of other adipogenic markers (such as SREBP1, FABP4, PLIN1, ADIPOQ and LEPTIN) and inflammatory markers (MCP1 and TNFα), whereas it enhances the expression levels of PGC1α (master regulator of mitochondrial biogenesis) and TBX1 (marker of “brite” cell)[1].
Dihydrocapsiate (25~200 μM; RAW 264.7 cells) prevents NO release and intracellular ROS generation[1].
Cell Viability Assay[1] | Cell Line: | Human preadipocytes | | Concentration: | 10, 25 and 50 μM | | Incubation Time: | 48 hours | | Result: | Did not affect cell viability. |
RT-PCR[1] | Cell Line: | Mature adipocytes | | Concentration: | 10 and 20 μM | | Incubation Time: | 8 days | | Result: | Markedly decreased the expression levels of other adipogenic markers (such as SREBP1, FABP4, PLIN1, ADIPOQ and LEPTIN) and inflammatory markers (MCP1 and TNFα), whereas it enhanced the expression levels of PGC1α (master regulator of mitochondrial biogenesis) and TBX1 (marker of “brite” cell). |
|
体内研究
(In Vivo) | Dihydrocapsiate (2 and 10 mg/kg; p.o.) improves morphometric parameters and insulin levels, prevents high fat diet (HFD)-induced adipocyte size and enhances energy expenditure-related genes in WAT, alleviates HFD-induced hepatic steatosis, prevents HFD-induced fat deposition and enhances mitochondrial biogenesis genes in BAT and improves intestinal morphology and modulates SCFA availability.
| Animal Model: | HFD-fed mice[1] | | Dosage: | 2 and 10 mg/kg | | Administration: | P.o. | | Result: | Improved morphometric parameters and insulin levels, prevented HFD-induced adipocyte size and enhanced energy expenditure-related genes in WAT, alleviated HFD-induced hepatic steatosis, prevented HFD-induced fat deposition and enhanced mitochondrial biogenesis genes in BAT and improved intestinal morphology and modulates SCFA availability. |
|
| Clinical Trial | |
| 分子量 | |
| 性状 | |
| Formula | |
| CAS 号 | |
| 结构分类 | |
| 来源 | - Plants
- Solanaceae
- Capsicum annuumL.
|
| 运输条件 | Room temperature in continental US; may vary elsewhere. |
| 储存方式 | -20°C, protect from light *In solvent : -80°C, 6 months; -20°C, 1 month (protect from light) |
m.cnreagent.com